Rociletinib, a third-generation EGFR-TKI targeting common EGFR-activating mutations, was found to increase the risk of corrected QT prolongation compared to chemotherapy (6.7 vs. 0%) in patients with advanced or metastatic NSCLC (127). Here, EGFR is linked to non-small cell lung carcinoma.